

Metastasiertes Nierenzellkarzinom – eine Übersicht über die aktuellen Erstlinientherapien (S. 8–12)

T. Hilser, C. Darr, V. Grünwald

Literatur:

1. Motzer RJ et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2018; 378(14): 1277–90
2. Motzer RJ et al. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). *Ann Oncol* 2021; 32: S685-S7
3. Rini BI et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. *J Clin Oncol* 2021; 39(15_suppl): 4500
4. Choueiri TK et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. *Ann Oncol* 2020; 31(8): 1030–9
5. Powles T et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. *J Clin Oncol* 2022; 40(6_suppl): 350
6. Motzer RJ et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. *Lancet Oncol* 2022; 23(7): 888–98
7. Motzer R et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med* 2021; 384(14): 1289–300
8. Motzer RJ et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. *Cancer* 2022; 128(11): 2085–97
9. Deutsche Krebsgesellschaft D. Konsultationsfassung, S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 3.0 https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Nierenzellkarzinom_Langversion_401.pdf. Juni 2022
10. Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med* 2007; 356(2): 115–24
11. Sternberg CN et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol* 2010; 28(6): 1061–8
12. Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. *J Clin Oncol*. 2013;31(30):3791-9.
13. Choueiri TK et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. *Eur J Cancer* 2018; 94: 115–25

14. Hudes G et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2007; 356(22): 2271–81
 15. Exelixis. Exelixis announces cabozantinib in combination with nivolumab and ipilimumab significantly improved progression-free survival in phase 3 COSMIC-313 pivotal trial in patients with previously untreated advanced kidney cancer. <https://irexelixiscom/news-releases/news-release-details/exelixis-announces-cabozantinib-combination-nivolumab-and>. 11. Juli 2022
-

Neue Behandlungsmöglichkeiten für Malignome der Kopfspeicheldrüsen

(S. 12–17)

C. Reichel

Literatur:

1. Mimica X et al. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. *Cancer* 2020; 126: 2153–62
2. Geiger JL et al. Management of Salivary Gland Malignancy: ASCO Guideline. *J Clin Oncol* 2021; 39:1909–41
3. Prosser JD et al. Trans-oral robotic submandibular gland removal. *J Robot Surg.* 2013; 7: 87–90
4. Yang TL. Robotic surgery for submandibular gland resection through a trans-hairline approach: The first human series and comparison with applicable approaches. *Head Neck* 2018; 40: 793–800
5. Capaccio P et al. Transoral robotic submandibular sialadenectomy: how and when. *Gland Surg* 2020; 9: 423–9
6. Floros P et al. Transoral robotic parapharyngeal approach to the submandibular space. *Head Neck* 2020; 42: 3776–8
7. Douglas JE et al. Robotic Management of Salivary Glands. *Otolaryngol Clin North Am* 2020; 53: 1051–64
8. Moffa A et al. Management of Parapharyngeal Space Tumor Using Transoral Robotic Surgery: The Tonsillar Fossa Battlefield. *J Craniofac Surg* 2020; 31: 1819–21
9. Lim JY et al. Comparison of Surgical Outcomes of Robotic and Conventional Approaches in Patients with Pre- and Poststyloid Parapharyngeal Space Tumors. *Ann Surg Oncol* 2020; 27: 4535–43
10. Venkatarthikeyan C et al. Robotic Surgery in Head and Neck in Pediatric Population: Our Experience. *Indian J Otolaryngol Head Neck Surg* 2020; 72: 98–103
11. Agulnik M et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. *J Clin Oncol* 2007; 25: 3978–84
12. Chau NG et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. *Ann Oncol* 2012; 23: 1562–70
13. Wong SJ et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. *Ann Oncol* 2016; 27: 318–23

14. Kurzrock R et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. *Ann Oncol* 2020; 31: 412–21
15. Foundation Medicine. Molecular targets in salivary gland cancers: A comprehensive genomic analysis of 1.666 cases. *ESMO 2022*; #660MO
16. Liu D et al. Pulmonary metastasectomy for head and neck cancers. *Ann Surg Oncol* 1999; 6: 572–8
17. Morris LGT et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. *JAMA Oncol* 2017; 3: 244–55
18. Ho AS et al. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. *J Clin Invest* 2019; 129: 4276–89
19. Ferrarotto et al. *ESMO 2020*; #919MO
20. Ho et al. *ESMO 2021*; #904b
21. Glisson B et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. *Clin Cancer Res* 2004;10: 944–6
22. Haddad R et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. *Oral Oncol* 2003; 39: 724–7
23. Bando et al. *ASCO 2021*; #6079
24. Takahashi H et al. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. *J Clin Oncol* 2019; 37: 125–34
25. Lee et al. Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11). *ASCO 2022*; abstract #6018
26. Hainsworth JD et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. *J Clin Oncol* 2018; 36: 536–42
27. Uijen et al. *ESMO 2021*; 911P
28. Fushimi C et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. *Ann Oncol* 2018; 29: 979–84
29. Locati LD et al. Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. *J Clin Oncol* 2021; 39: 4061–8
30. Westphalen CB et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. *NPJ Precis Oncol* 2021; 5: 69
31. Drilon A et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med* 2018; 378: 731–9
32. Doebele RC et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020; 21: 271–82
33. *ESMO 2022*; #667P
34. *ESMO 2022*; #463P
35. Cristescu R et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science* 2018; 362(6411): eaar3593

36. Linxweiler M et al. The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. *Clin Cancer Res* 2020; 26: 2859–70
 37. Cohen RB et al. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. *Am J Clin Oncol* 2018; 41: 1083–8
 38. Rodriguez CP et al. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. *Clin Cancer Res* 2020; 26: 837–45
-

Update: Aktuelle Therapiestandards beim Pankreaskarzinom (S. 28–36)

D. Zhang, K. Dorman, C. B. Westphalen, M. Haas, V. Heinemann und S. Böck

Literatur:

1. Krebs – Bauchspeicheldrüsenkrebs.
(https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Bauchspeicheldruesenkrebs/bauchspeicheldruesenkrebs_node.html) Zugegriffen am 26.08.2022
2. Siegel RL et al. Cancer Statistics 2021. *CA Cancer J Clin* 2021; 71(1): 7–33
3. Conroy T et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med* 2018; 379(25): 2395–406
4. Hruban RH et al. Why is pancreatic cancer so deadly? The pathologist's view. *J Pathol* 2019; 248(2): 131–41
5. Grant TJ et al. Molecular Pathogenesis of Pancreatic Cancer. *Prog Mol Biol Transl Sci* 2016; 144: 241–75
6. McGuigan A et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. *World J Gastroenterol* 2018; 24(43): 4846–61
7. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. *Nat Rev Gastroenterol Hepatol* 2021; 18(7): 493–502
8. Seufferlein T et al. S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL. *Z Gastroenterol* 2022; 60(6): 991–1037
9. Vincent A et al. Pancreatic cancer. *Lancet* 2011; 378(9791): 607–20
10. Ghaneh P et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. *Health Technol Assess* 2018; 22(7): 1–114
11. Al-Hawary M BS et al. NCCN Guidelines Version 1.2022 Pancreatic Adenocarcinoma.
(https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.) Zugegriffen am 14.08.2022
12. van der Gaag NA et al. Preoperative biliary drainage for cancer of the head of the pancreas. *N Engl J Med* 2010; 362(2): 129–37
13. Oettle H et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. *Jama* 2013; 310(14): 1473–81
14. Conroy T et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. *JAMA Oncology* 2022; e223829
15. Daamen LA et al. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. *Ann Surg* 2022; 275(4): 769–75

16. Versteijne E et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. *J Clin Oncol* 2022; 40(11): 1220–30
17. Springfield C & JP Neoptolemos. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. *Nat Rev Clin Oncol* 2022; 19(5): 285–6
18. Kunzmann V et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. *Lancet Gastroenterol Hepatol* 2021; 6(2): 128–38
19. Hartlapp I et al. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). *ESMO Open* 2022; 7(4): 100552
20. Fietkau R et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial. *Journal of Clinical Oncology* 2022; 40(16_suppl): 4008–4008
21. Katz MHG et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. *JAMA Oncol* 2022; 8(9): 1263–70
22. Taieb J & Abdallah R. How I treat pancreatic cancer. *ESMO Open* 2020; 4(Suppl 2): e000818
23. Glimelius B et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. *Ann Oncol* 1996; 7(6): 593–600
24. Arends J et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. *Clin Nutr* 2006; 25(2): 245–59
25. Burris HA 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; 15(6): 2403–13
26. Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; 364(19): 1817–25
27. Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; 369(18): 1691–703
28. Klein-Brill A et al. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. *JAMA Netw Open* 2022; 5(6): e2216199
29. Santucci J et al. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. *Eur J Cancer* 2022; 174: 102–12
30. Carrato A et al. Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial. *Journal of Clinical Oncology* 2022; 40(16_suppl): 4022–4022
31. Portal A et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. *Br J Cancer* 2015; 113(7): 989–95
32. Fouchardiere CDI. LBA60 - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study. *ESMO Congress* 2022.
33. Oettle H et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. *J Clin Oncol* 2014; 32(23): 2423–9
34. Wang-Gillam A et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. *Eur J Cancer* 2019; 108: 78–87

35. Mosele F et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann Oncol* 2020; 31(11): 1491–505
36. Luo J. KRAS mutation in pancreatic cancer. *Semin Oncol* 2021; 48(1): 10–8
37. Leidner R et al. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. *N Engl J Med* 2022; 386(22): 2112–9
38. Philip PA et al. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. *Clin Cancer Res* 2022; 28(12): 2704–14
39. Qin S et al. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. *Journal of Clinical Oncology* 2022; 40(17_suppl): LBA4011–LBA4011
40. Europeans Medicines Agency: Lynparza. (<https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza>). Zugegriffen am 26.08.2022
41. Sunada S et al. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer. *Cancer Sci* 2018; 109(4): 893–9
42. Golan Tet al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med* 2019; 381(4): 317–27
43. Kindler HL et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *J Clin Oncol* 2022: Jco2101604
44. Peyraud F & Italiano A. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. *Cancers (Basel)* 2020; 12(6)
45. Sohal DPS et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. *J Clin Oncol* 2020: Jco2001364
46. European Medicines Agency: Vitrakvi. (<https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi>). Zugegriffen am 26.08.2022
47. Delgado J et al. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. *ESMO Open* 2021; 6(2): 100087
48. Garcia-Foncillas J et al. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. *Cancers (Basel)* 2022; 14(7)
49. Lemery S et al. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. *N Engl J Med* 2017; 377(15): 1409–12
50. Coston T et al. Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series. *Journal of Clinical Oncology* 2022; 40(16_suppl): 4145–4145
51. Marabelle A et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol* 2020; 38(1): 1–10
52. Padrón LJ et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. *Nat Med* 2022; 28(6): 1167–77
53. Balachandran VP et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. *Journal of Clinical Oncology* 2022; 40(16_suppl): 2516–2516